Front Barnett Associates LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,024 shares of the biopharmaceutical company’s stock after buying an additional 700 shares during the period. Front Barnett Associates LLC’s holdings in Pfizer were worth $494,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Navellier & Associates Inc bought a new position in Pfizer during the second quarter valued at approximately $225,000. KBC Group NV increased its position in Pfizer by 6.4% in the second quarter. KBC Group NV now owns 2,720,292 shares of the biopharmaceutical company’s stock valued at $95,781,000 after buying an additional 164,053 shares during the period. Swiss National Bank increased its position in shares of Pfizer by 8.4% in the second quarter. Swiss National Bank now owns 18,298,389 shares of the biopharmaceutical company’s stock worth $644,286,000 after buying an additional 1,412,800 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Pfizer by 5.0% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 232,200 shares of the biopharmaceutical company’s stock worth $8,176,000 after buying an additional 11,030 shares during the last quarter. Finally, RFG Advisory Group LLC increased its position in shares of Pfizer by 16.4% in the second quarter. RFG Advisory Group LLC now owns 17,031 shares of the biopharmaceutical company’s stock worth $600,000 after buying an additional 2,394 shares during the last quarter. 69.65% of the stock is owned by institutional investors and hedge funds.
Pfizer Inc. (NYSE:PFE) traded down 1.97% during midday trading on Thursday, hitting $33.32. 24,762,484 shares of the stock traded hands. The stock has a market cap of $202.11 billion, a price-to-earnings ratio of 29.54 and a beta of 0.87. The company has a 50-day moving average price of $34.57 and a 200 day moving average price of $34.02. Pfizer Inc. has a one year low of $28.25 and a one year high of $37.39.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.02. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The firm had revenue of $13.10 billion for the quarter, compared to the consensus estimate of $13.01 billion. During the same period in the prior year, the firm earned $0.56 EPS. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post $2.46 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be paid a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 3.53%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s payout ratio is currently 95.24%.
A number of research analysts recently commented on the stock. Barclays PLC reaffirmed an “equal weight” rating and issued a $34.00 price target on shares of Pfizer in a report on Tuesday, August 2nd. Sanford C. Bernstein set a $38.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, August 2nd. Vetr downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $37.97 price target for the company. in a report on Thursday, July 14th. Jefferies Group set a $40.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Monday, August 1st. Finally, JPMorgan Chase & Co. set a $40.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Monday, July 25th. Ten research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $38.78.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.